A Correlation Analysis Of Clinical Efficacy Of Gefitinib For Patitents With Advanced NSCLC And Type Of Cold Or Heat Syndrome

Object:To investigate the Progression-Free-Survival(PFS) of patients received gefitinib with advanced non-small-cell lung cancer(NSCLC) with different TCM (cold, heat) syndrome, and to provide a traditional Chinese medicine basis for predicting the efficacy of gefitinib in patients with advanced non-small-cell lung cancer.Method:Selecting the advanced NSCLCinpatients and outpatients from January 2014 to June 2015 in Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. Patients with TCM syndrome information collection, according to the theory of traditional Chinese medicine were divided into two groups of cold and heat.To observing the changes of PFS afte receiving gefitinib in different patients. To investigate the relationship between gefitiniband TCM drugs of cold and heat syndrome.Result:1?PFS for all patients was (10.2±4.3) months. Among the 38 patients with cold syndrome, PFS was (10.5±3.1) months,25 patients with heat syndrome PFS was (8.5±3.8) months. Cold syndrome patients with heat syndrome in patients with PFS has certain advantages (P=0.026).2?PFS was (8.5±3.2) months in 23 male patients and 40 female patients with PFS (10.6±3.9) months. PFS of female patients was longer than the PFS of male patients (P=0.032).3?PFS was (8.5±2.4) months in 22 smoking patients, and the PFS was (10.5±4.2) months in 41 patients without smoking.PFS ofnon smoking patients was longer thanPFS of smoking patients (P=0.044).4?PFS of 54 patients with adenocarcinoma was(10.5±3.4) months, PFS of 9 patients with squamous cell carcinoma of were (7.5±2.2) months. PFS ofthe patients with adenocarcinoma was longer than the PFS of patients with adenocarcinoma of the PFS (P=0.013).5?PFS of 45 patients which were used to undergo chemotherapy was(10.5±3.4) months, while PFS of 18 patients without chemotherapy was (8.5±2.9) months. The PFS of chemotherapy group was longer than the PFS of no chemotherapy group. (P=0.032).6?Women with cold syndrome in 22 patients, PFS was(11.5±2.8) months,18 patients with heat syndrome, PFS was (9.5±2.9) months. PFS of patients with cold syndrome was significantly longer than that with heat syndrome. (P=0.033)7?Non smoking patients with cold syndrome in 24 patients, PFS was(11.4±2.8) months,17 patients with heat syndrome, PFS was (9.5±2.6) months. PFS of patients with cold syndrome was significantly longer than that with heat syndrome. (P=0.034)8?Adenocarcinoma patients with cold syndrome in 34 patients, PFS was(10.6±2.4) months,20 patients with heat syndrome, PFS was (8.6±3.2) months. PFS of patients with cold syndrome was significantly longer than that with heat syndrome. (P=0.012)9?Chemotherapy patients with cold syndrome in 30 patients, PFS was (10.8±2.4) months,20 patients with heat syndrome, PFS was (8.8±3.2) months. PFS of patients with cold syndrome was significantly longer than that with heat syndrome. (P=0.023)10?Patients of EGFR mutationwith cold syndrome in 33 patients, PFS was(10.5±2.8) months,24 patients with heat syndrome, PFS was (8.5±3.8) months. PFS of patients with cold syndrome was significantly longer than that with heat syndrome. (P=0.026)Conclusion:1?Patients with cold syndrome was more than that with heat syndrome in advanced NSCLC patients of EGFR mutation.2?The effect of Gefitinib was associated with cold or heat syndrome type, PFS of patients with cold syndrome was longer than that with heat syndrome.3?In the dominant population of Gefitinib, PFS of patients with cold syndrome was longer than that with heat syndrome.